ADOCIA Reports Third Quarter 2026 Financial Results and Provides a Business Update
LYON, France, October 29, 2026--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC, the "Company"), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of metabolic diseases including diabetes and obesity, reports financial results for the third quarter of 2026 and provides a business update.
LYON, France, October 29, 2026--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC, the "Company"), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of metabolic diseases including diabetes and obesity, reports financial results for the third quarter of 2026 and provides a business update.
What's Your Reaction?
